Mutations in the HFE, TFR2, and SLC40A1 genes in patients with hemochromatosis

Gene

Volumn 508, Issue 1, 2012, Pages 15-20

  del Castillo Rueda, Alejandro ^a,c   Moreno Carralero, María Isabel ^b   Cuadrado Grande, Nuria ^b   Álvarez Sala Walther, Luis Antonio ^a,c   Enríquez de Salamanca, Rafael ^b,c   Méndez, Manuel ^b   Morán Jiménez, María Josefa ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Dysmetabolic iron overload syndrome (DIOS); Ferroportin (SLC40A1); Hereditary hemochromatosis; HFE; Hyperferritinemia; Transferrin receptor 2 (TFR2)

Indexed keywords

FERROPORTIN; TRANSFERRIN RECEPTOR 2;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; GENE; GENE MUTATION; GENOTYPE; HEMOCHROMATOSIS; HETEROZYGOTE; HUMAN; HYPERFERRITINEMIA; IRON OVERLOAD; MALE; METABOLIC SYNDROME X; PHENOTYPE; PHLEBOTOMY; PRIORITY JOURNAL;

ADULT; CATION TRANSPORT PROTEINS; DNA; FEMALE; GENOTYPE; HEMOCHROMATOSIS; HETEROZYGOTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; IRON OVERLOAD; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTORS, TRANSFERRIN;

EID: 84865531574     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.07.069     Document Type: Article

References (37)

1. Alexander J., Kowdley K.V. HFE-associated hereditary hemochromatosis. Genet Med 2009, 11:307-313.
2. Allen K.J., et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 2008, 358:221-230.
3. Auriac A., Willemetz A., Canonne-Hergaux F. Lipid raft-dependent endocytosis: a new route for hepcidin-mediated regulation of ferroportin in macrophages. Haematologica 2010, 95:1269-1277.
4. Bach V., Remacha A., Altes A., Barcelo M.J., Molina M.A., Baiget M. Autosomal dominant hereditary hemochromatosis associated with two novel Ferroportin 1 mutations in Spain. Blood Cells Mol. Dis. 2006, 36:41-45.
5. Beutler E., Griffin M.J., Gelbart T., West C. A previously undescribed nonsense mutation of the HFE gene. Clin. Genet. 2002, 61:40-42.
6. Biasiotto G., Camaschella C., Forni G.L., Polotti A., Zecchina G., Arosio P. New TFR2 mutations in young Italian patients with hemochromatosis. Haematologica 2008, 93:309-310.
7. Brogna S., Wen J. Nonsense-mediated mRNA decay (NMD) mechanisms. Nat. Struct. Mol. Biol. 2009, 16:107-113.
8. Camaschella C., Poggiali E. Rare types of genetic hemochromatosis. Acta Haematol. 2009, 122:140-145.
9. Camaschella C., Poggiali E. Towards explaining "unexplained hyperferritinemia". Haematologica 2009, 94:307-309.
10. Chang Y.F., Imam J.S., Wilkinson M.F. The nonsense-mediated decay RNA surveillance pathway. Annu. Rev. Biochem. 2007, 76:51-74.
11. Chen L.Y., et al. Dysmetabolic hyperferritinemia is associated with normal transferrin saturation, mild hepatic iron overload, and elevated hepcidin. Ann. Hematol. 2011, 90:139-143.
12. Delaby C., Pilard N., Goncalves A.S., Beaumont C., Canonne-Hergaux F. Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood 2005, 106:3979-3984.
13. Dongiovanni P., Fracanzani A.L., Fargion S., Valenti L. Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J. Hepatol. 2011, 55:920-932.
14. Drakesmith H., et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 2005, 106:1092-1097.
15. EASL EASL clinical practice guidelines for HFE hemochromatosis. J. Hepatol. 2010, 53:3-22.
16. Fleming R.E., Ponka P. Iron overload in human disease. N. Engl. J. Med. 2012, 366:348-359.
17. Gerolami V., Le Gac G., Mercier L., Nezri M., Berge-Lefranc J.L., Ferec C. Early-onset haemochromatosis caused by a novel combination of TFR2 mutations(p.R396X/c.1538-2 A>G) in a woman of Italian descent. Haematologica 2008, 93:e45-e46.
18. Mariani R., et al. Genetic and metabolic factors are associated with increased hepatic iron stores in a selected population of p.Cys282Tyr heterozygotes. Blood Cells Mol. Dis. 2010, 44:159-163.
19. Marro S., et al. Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position -7007 of the FPN1 promoter. Haematologica 2010, 95:1261-1268.
20. Mattman A., et al. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood 2002, 100:1075-1077.
21. Mayr R., et al. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J. Hepatol. 2010, 53:941-949.
22. Mendell J.T., Sharifi N.A., Meyers J.L., Martinez-Murillo F., Dietz H.C. Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nat. Genet. 2004, 36:1073-1078.
23. Mendes A.I., et al. Non-classical hereditary hemochromatosis in Portugal: novel mutations identified in iron metabolism-related genes. Ann. Hematol. 2009, 88:229-234.
24. Muckenthaler M.U., Galy B., Hentze M.W. Systemic iron homeostasis and the iron-responsive element/iron-regulatory protein (IRE/IRP) regulatory network. Annu. Rev. Nutr. 2008, 28:197-213.
25. Mura C., Le Gac G., Jacolot S., Ferec C. Transcriptional regulation of the human HFE gene indicates high liver expression and erythropoiesis coregulation. FASEB J. 2004, 18:1922-1924.
26. Nemeth E., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306:2090-2093.
27. Pelucchi S., et al. Expression of hepcidin and other iron-related genes in type 3 hemochromatosis due to a novel mutation in transferrin receptor-2. Haematologica 2009, 94:276-279.
28. Pietrangelo A. The ferroportin disease. Blood Cells Mol. Dis. 2004, 32:131-138.
29. Pietrangelo A., et al. Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease. Blood Cells Mol. Dis. 2006, 37:192-196.
30. Pietrangelo A., Caleffi A., Corradini E. Non-HFE hepatic iron overload. Semin. Liver Dis. 2011, 31:302-318.
31. Piperno A., et al. Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis. Gastroenterology 2000, 119:441-445.
32. Riva A., et al. Revaluation of clinical and histological criteria for diagnosis of dysmetabolic iron overload syndrome. World J. Gastroenterol. 2008, 14:4745-4752.
33. Rochette J., Le Gac G., Lassoued K., Ferec C., Robson K.J. Factors influencing disease phenotype and penetrance in HFE haemochromatosis. Hum. Genet. 2010, 128:233-248.
34. Ruivard M., et al. Iron absorption in dysmetabolic iron overload syndrome is decreased and correlates with increased plasma hepcidin. J. Hepatol. 2009, 50:1219-1225.
35. Salvioni A., et al. Prevalence of C282Y and E168X HFE mutations in an Italian population of Northern European ancestry. Haematologica 2003, 88:250-255.
36. Valenti L., et al. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica 2007, 92:1037-1042.
37. Valenti L., Dongiovanni P., Fargion S., Fracanzani A.L. Iron genes, dysmetabolism and fibrosis in chronic hepatitis C. J. Hepatol. 2008, 48:513-514. (author reply 514-5).